Muyldermans Astrid, Florin Lisa, Devos Helena, Cauwelier Barbara, Emmerechts Jan
a Department of Laboratory Hematology , AZ Sint-Jan Hospital , Bruges , Belgium.
Hematology. 2019 Dec;24(1):166-172. doi: 10.1080/10245332.2018.1535536. Epub 2018 Oct 18.
The diagnosis of myelodysplastic syndrome (MDS) is not always straightforward in the absence of objective markers such as ringed sideroblasts, an excess of blasts or clonal cytogenetic abnormalities. Moreover, the lack of specificity of morphological dysplasia makes the differentiation between MDS and other causes of peripheral cytopenia difficult. The WHO 2016 classification of MDS recognizes multiparameter flow cytometry (MFC) as an adjuvant tool for MDS diagnosis. An easily applicable MFC protocol based on CD34 and CD45 is proposed by Ogata et al. Furthermore, in the diagnostic workup of patients with peripheral cytopenia, the integration of MFC by means of a Lymphoid Screening Tube (LST) is recommended by the EuroFlow™ consortium. The aim of this study was to investigate whether the LST, supplemented with CD34, can be used to calculate the Ogata score, thereby obviating the need to run different flow cytometric tubes.
Bone marrow samples from 108 patients with peripheral cytopenia were analyzed (MDS n = 32; non-MDS n = 76). The LST used in the present study was based on the tube designed by the EuroFlow™ consortium, but with addition of CD34 and without TCRγδ.
Rather low sensitivities of 55% in low-grade MDS patients and 80% in high-grade MDS patients were observed. However, a high specificity of 92% was found in the non-MDS group.
Besides screening for clonal lymphocytes, plasma cells and blasts, an LST supplemented with CD34 allows the calculation of the Ogata score as an adjuvant tool in the diagnostic workup of cytopenic patients suspected of MDS.
在缺乏如环形铁粒幼细胞、原始细胞增多或克隆性细胞遗传学异常等客观标志物的情况下,骨髓增生异常综合征(MDS)的诊断并非总是一目了然。此外,形态学发育异常缺乏特异性,使得MDS与其他导致外周血细胞减少的原因难以区分。世界卫生组织2016年MDS分类将多参数流式细胞术(MFC)视为MDS诊断的辅助工具。绪方等人提出了一种基于CD34和CD45的易于应用的MFC方案。此外,在对外周血细胞减少患者的诊断检查中,欧洲流式细胞术(EuroFlow™)联盟建议通过淋巴细胞筛选管(LST)整合MFC。本研究的目的是调查补充CD34的LST是否可用于计算绪方评分,从而无需运行不同的流式细胞管。
分析了108例外周血细胞减少患者的骨髓样本(MDS患者32例;非MDS患者76例)。本研究中使用的LST基于EuroFlow™联盟设计的管型,但添加了CD34且不含TCRγδ。
在低级别MDS患者中观察到的敏感性相当低,为55%,在高级别MDS患者中为80%。然而,在非MDS组中发现特异性较高,为92%。
除了筛选克隆性淋巴细胞、浆细胞和原始细胞外,补充CD34的LST可用于计算绪方评分,作为疑似MDS的血细胞减少患者诊断检查的辅助工具。